Back to Peptides
Vesugen
Cardiovascular & Vascular SupportVesugen is a synthetic peptide studied for its potential vascular-regulatory effects. It is derived from DNA-regulating peptide complexes and has been evaluated in Russia for its effects on endothelial function and cardiovascular aging.
Reconstitute
3 mL BAC + 20mg vial
67 mcg/unit
Daily Range
0.5–2 mg Subcutaneous (SQ)
Once daily for 10–20 days
Standard Dose
1 mg
Cycle
4–8 weeks
then reassess
Vesugenvascular peptideendothelial repairanti-agingcapillary regeneration
Dosing & Reconstitution Guide
Research doses range from 50–200 μg per day for 10–15 days. No human therapeutic protocols are authorized outside regulated clinical studies.
Standard / Gradual Approach
20mg VialstandardPhaseDoseVolume
Week 1500 mcg (0.5 mg)7.5 units (0.075 mL)
Week 21000 mcg (1.0 mg)15 units (0.15 mL)
Week 31500 mcg (1.5 mg)22.5 units (0.225 mL)
Weeks 4–8+1500–2000 mcg (1.5–2.0 mg)22.5–30 units (0.225–0.30 mL)
Protocol Summary
Subcutaneous (SQ): Once daily for 10–20 days · Dose range 0.5–2 mg with gradual titration
Cycle Length: 4–8 weeks typical; reassess before extending
Frequency & Cycling
SubQ Injection
Administer daily for 10–20 days. Repeat cycle every 3–6 months for vascular maintenance or recovery.
🧪 Quick Start
Vial Size
20 mg
BAC Water
3 mL
Concentration
6.67 mcg/unit
Starting Dose
500 mcg (0.5 mg) (7.5 units (0.075 mL))
Maintenance Dose
1500–2000 mcg (1.5–2.0 mg) (22.5–30 units (0.225–0.30 mL))
Potential Benefits & Use Cases
Vesugen is a peptide for experimental research use only. Not FDA- or EMA-approved.
May support vascular endothelial cell proliferation and renewal through Ki-67 gene regulation (preclinical)
Improves memory and attention in elderly with functional CNS disorders via oral application (limited human data)
May restore synaptic plasticity in Alzheimer's disease models (in vitro)
Regulates Alzheimer's-related genes (SUMO, APOE, IGF1) and aging genes (p16, p21) (preclinical)
Clinical data Strong preclinical Limited data
Mechanism of Action
→Regulates gene expression of vascular wall endothelial cells
→Supports extracellular matrix remodeling and vascular elasticity
→May stabilize microcirculation and reduce endothelial permeability
Lifestyle & Optimization
timing
Consistent daily dosing.
diet
Heart-healthy diet rich in antioxidants and omega-3s.
exercise
Regular cardiovascular exercise.
sleep
Adequate sleep and stress management.
Peptide Research & Preclinical Studies
Evidence-Based Research Findings
Study TitleType
Side Effects & Safety
Common Side Effects
• Mild nausea (<5%), occasional headaches (<3%), minor digestive upset (user-reported)
Contraindications & Warnings
• Drug interactions with statins/ACE inhibitors untested
🧮 Dose Calculator
Concentration
66.7
mcg/unit
Draw Volume
7
units (0.070 mL)
For a 500 mcg dose, draw 7 units on a U-100 insulin syringe
🧬
Bioavailability & Absorption
SubQ Injection
High systemic exposure and distribution to vascular endothelial cells
Oral Administration
Low; not recommended due to degradation
Half-Life
Estimated 3–4 hours
Degradation
Metabolized by renal and hepatic peptidases
Tissue Specificity
Acts primarily on capillaries, vascular smooth muscle, and endothelial tissues
⚗️
Peptide Details
Molecular Weight
390.39
Formula
C15H26N4O8
Sequence
Lys-Glu-Asp
⚖️
Legal Status & Regulatory
RegionStatus
FDANot Approved
EUNot Approved
AustraliaNot Approved
CanadaNot Approved
Storage Instructions
Lyophilized (Powder)
freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles
Reconstituted (Mixed)
Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw